Piper Sandler lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $533 from $535 and keeps an Overweight rating on the shares ahead of earnings. With biotech having largely underperformed in 2024 and with several macro headwinds expected this year, the firm thinks the phrase “stock pickers market” may never be more appropriate than right now. Given these factors, Piper is taking the time to finetune its price targets and layer in additional Q4pre-releases for a number of names. Bottom line, despite meaningful macro factors in 2025, the firm believes several large and mid-cap names with fundamental drivers may severe as excellent vehicles for upside this year.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley
- Bargain Basement CRISPR Therapeutics Becomes Takeover Target
- Vertex a ‘core large-cap biotech holding,’ says JPMorgan
- Vertex Pharmaceuticals price target lowered to $456 from $476 at Morgan Stanley
- Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement